Top 10 Multiple Sclerosis Studies of 2018
From clinical trials evaluating treatments to studies unearthing new discoveries about the disease's mechanism, these were some of the top newsworthy moments in multiple sclerosis research in 2018.
From clinical trials evaluating treatments to studies unearthing new discoveries about the disease's mechanism, these were some of the top newsworthy moments in multiple sclerosis research in 2018.
10. Synthetic Compound Can Potentially Treat Myelin Loss in Multiple Sclerosis
A synthetic compound has demonstrated the ability to remyelinate damaged axons and alter the immune system, highlighting a promising new way of treating multiple sclerosis. Read more here.
9. Study: Epstein-Barr Virus Infection Linked with Multiple Sclerosis
A study links Epstein-Barr virus (EBV) infection with multiple sclerosis, confirming evidence from previous studies and providing support for targeting EBV-infected immune cells associated with chronic MS lesions as a potential treatment.
8. Novel Mechanism of Demyelination Discovered in Multiple Sclerosis
Blocking a type of cell death that occurs in multiple sclerosis could be a way to reduce demyelination and neurodegeneration, potentially leading to new therapeutic targets.
7. Study: Epigenetic Mechanism May Trigger Multiple Sclerosis
A newly discovered mechanism may provide insight into a major risk gene for multiple sclerosis that triggers the disease through epigenetic regulation.
6. Multiple Sclerosis Drug Demonstrates Sustained Efficacy in 2-Year Extension Study
In a 2-year extension study, treatment with ozanimod effectively reduced disease activity in patients with relapsing-remitting multiple sclerosis.
5.
New Research Highlights Pathogenic Role of B Cells in Multiple Sclerosis
While T cells have been known to play a role in the pathogenesis of multiple sclerosis (MS), new research indicates that T cell interactions with B cells may drive inflammation and brain lesions in the disease.
4. Novel Multiple Sclerosis Subtype Discovered
For the first time, new findings have identified a novel subtype of MS that occurs without cerebral white matter demyelination.
3. Potential Multiple Sclerosis Trigger Identified
Researchers have identified a potential trigger of multiple sclerosis (MS), moving a step closer to a better understanding of the disease.
2. Siponimod May Delay Disability Progression in Secondary Progressive Multiple Sclerosis
The study met its primary endpoint of substantial reductions in 3- and 6-month confirmed disability progression with siponimod compared with placebo and suggested that siponimod is associated with other benefits related to MS disease activity.
1. Molecular Therapy Sparks Remyelination, Hope for MS Cure
An experimental treatment was able to restore myelin, improve limb function, and reduce discomfort on peripheral nerves in mice.
